Arrowhead Pharmaceuticals

This study tested whether an investigational drug called ARO-ANG3, given as injections under the skin, could safely lower unhealthy levels of fats in the blood (mixed dyslipidemia). It involved 204 adults who were already on stable cholesterol medication. Participants received ei…

This small, early-stage study tested an investigational drug called fazirsiran in people with liver disease caused by Alpha-1 antitrypsin deficiency. Sixteen participants received multiple injections under the skin to see if the drug could safely reduce the harmful protein that b…

This study tested the safety and effects of an inhaled drug called ARO-MMP7 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. The goal was to see if the drug was safe and how it behaved in the body. The study involved 105 …

This early-stage study tested the safety and effects of an experimental drug called ARO-C3. It involved 62 healthy volunteers and patients with rare kidney diseases (C3G and IgAN). The goal was to see how the body processes the drug and determine safe dose levels for future resea…

This study tested a new inhaled drug called ARO-RAGE to see if it is safe and how it behaves in the body. It involved 127 healthy volunteers and people with asthma. The main goal was to check for side effects and measure how the drug moves through the body, with some tests on lun…

This was the first study in people to test the safety of an experimental drug called ARO-ANG3, which is designed to lower unhealthy cholesterol and triglyceride levels. It involved 93 healthy volunteers and patients with high cholesterol or triglycerides. The main goal was to see…

This early-stage study tested a new drug called ARO-HIF2 in 26 patients with advanced kidney cancer that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the body processes the drug. Researchers also looked for early signs that th…

This early-stage study tested a new drug called ARO-HBV for treating Hepatitis B. It first checked the drug's safety in healthy volunteers, then looked at its effects in people with the virus. The main goal was to see if the drug was safe and how the body processed it, while also…

This early-stage study tested a new drug called ARO-APOC3 to see if it is safe for people. It involved 112 healthy adults and patients with very high levels of blood fats (triglycerides), including a rare genetic condition. The main goal was to check for side effects and see how …

This early-stage study tested a new drug called ARO-HSD to see if it is safe and how it behaves in the body. It involved 50 healthy volunteers and patients with a serious form of fatty liver disease called NASH. The main goal was to check for side effects and measure how the drug…

This study tested an investigational injection called fazirsiran in 40 people with Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can cause liver disease. The main goal was to see if the drug was safe and if it could reduce the levels of a harmful protein that bu…

This study followed 418 adults with high cholesterol and triglycerides who had already completed a previous 12-month trial of the experimental drug ARO-APOC3. Participants received the medication every 3-6 months to evaluate long-term safety and how well it continues to control c…

This study tested whether an experimental drug called plozasiran (ARO-APOC3) could safely and effectively lower unhealthy levels of fats and cholesterol in the blood, a condition called mixed dyslipidemia. Over 350 adults already on standard cholesterol medication were randomly a…

This study tested whether an experimental injection called ARO-APOC3 could safely and effectively lower very high levels of triglycerides, a type of fat in the blood. 229 adults with severe hypertriglyceridemia received either the drug or a placebo shot. The main goal was to see …

This early-stage study tested the safety of an experimental drug called ARO-AAT in 45 healthy volunteers. Researchers wanted to understand how the body processes the drug and whether it affects levels of the Alpha-1 protein. The study focused on identifying side effects and deter…

This early-stage study aimed to check the safety and see how the body processes a new experimental drug called ARC-520, which is designed to treat hepatitis B. It involved 40 healthy adult volunteers who received a single dose of the drug through an IV. The main goal was to find …

This early-stage study tested the safety and how the body processes ARC-520 in healthy adults. Researchers gave increasing doses to 54 volunteers to check for side effects and measure drug levels in the blood. The goal was to gather basic safety information before testing in pati…